Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
08/10/2024 10:40
LONDON, Oct 8 (Reuters) - Pfizer PFE.N and its German
partner BioNTech 22UAy.DE on Tuesday won their attempt to
invalidate two of rival CureVac's 5CV.DE patents at London's
High Court.
Pfizer and BioNTech had filed their lawsuit in September
2022 over patents relating to messenger RNA (mRNA) technology,
which underpins Pfizer and BioNTech's COVID-19 vaccine.
(Reporting by Sam Tobin; Editing by Sachin Ravikumar)
((Sam.Tobin@thomsonreuters.com;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028